Search - tctmd.com

Displaying 381 - 400 of 411

Sort: Relevancy | Date

Presentation ESC 2013

Apixaban versus Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Findings from the ARISTOTLE Trial

Presenter: Alvaro Avezum

September 03, 2013

Presentation

Atrial Fibrillation in MI Patients: Impact on Health Care Utilization

Presenter: A.M. Chamberlain

August 27, 2013

Presentation

Apixaban Vs. Warfarin in Patients with Atrial Fibrillation According to Prior Warfarin Use

Presenter: David Garcia

August 05, 2013

Presentation

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Presenter: Stefan H. Hohnloser

August 01, 2013

Presentation

Risks and Benefits of Anticoagulation in Atrial Fibrillation

Presenter: MW Cullen

June 20, 2013

Presentation TVT 2013

Predictors of TAVR: Associated Strokes: New Onset Atrial Fibrillation, Postdilatation, and Others

Presenter: Josep Rodes-Cabau

June 12, 2013

Presentation Fellows 2013

LAA Closure for Nonvalvular Atrial Fibrillation

Presenter: Mark Reisman

April 17, 2013

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

Presentation ECHO 2013

Advanced TEE: Clinical Decision Making in Cryptogenic Stroke and Atrial Fibrillation

Presenter: Marco R. Di Tullio

April 04, 2013

Presentation ACC 2013

Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL)

Presenter: David R. Holmes, Jr.

March 08, 2013

Presentation TCT 2013

Impact of Atrial Fibrillation in Patients with STEMI Before and After Primary PCI: Insights from the HORIZONS-AMI Trial

Presenter: A. Rene, Philippe Genereux, Michael Ezekowitz, Ajay Kirtane, Roxana Mehran, Gregg Stone

January 31, 2013

Presentation TCT 2013

Cost-effectiveness Of Transcatheter Left Atrial Appendage Occlusion Compared With 5 Alternative Anticoagulation Strategies For Stroke Prevention In Atrial Fibrillation: A Markov...

Presenter: Bryan Yan, Chow Innes, Yat Yin Lam, Vivian Lee, Cheuk Man Yu

January 31, 2013

Presentation TCT 2012

Novel Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation

Presenter: Jonathan Halperin

October 25, 2012

Presentation TCT 2012

4q25 and Prediction of Atrial Fibrillation: How Can This Information Help the Clinician?

Presenter: Paddy Barrett

October 25, 2012

Presentation TCT 2012

Will Transcatheter Left Atrial Appendage Closure Transform Management of Atrial Fibrillation?

Presenter: Vivek Reddy

October 25, 2012

Presentation TCT 2012

Lone Surgical Treatment of Atrial Fibrillation: Meaningful Progress in the Past 15 Years?

Presenter: William Cohn

October 24, 2012

Presentation TCT 2012

Does Atrial Fibrillation Ablation Reduce Cardioembolic Stroke?

Presenter: Vivek Reddy

October 24, 2012

Presentation TCT 2012

Case 4: The Patient with Atrial Fibrillation Presenting with an Acute Coronary Syndrome

Presenter: Michael Ezekowitz

October 24, 2012

Presentation TCT 2012

Anticoagulation Choices for Atrial Fibrillation: Which Drug for Which Patient?

Presenter: Michael Ezekowitz

October 24, 2012

Presentation TCT 2012

Strategies for the ACS Patient with Chronic Atrial Fibrillation

Presenter: C. Michael Gibson

October 24, 2012

Advertisement

Apixaban versus Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Findings from the ARISTOTLE Trial

Atrial Fibrillation in MI Patients: Impact on Health Care Utilization

Apixaban Vs. Warfarin in Patients with Atrial Fibrillation According to Prior Warfarin Use

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Risks and Benefits of Anticoagulation in Atrial Fibrillation

Predictors of TAVR: Associated Strokes: New Onset Atrial Fibrillation, Postdilatation, and Others

LAA Closure for Nonvalvular Atrial Fibrillation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Advanced TEE: Clinical Decision Making in Cryptogenic Stroke and Atrial Fibrillation

Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL)

Impact of Atrial Fibrillation in Patients with STEMI Before and After Primary PCI: Insights from the HORIZONS-AMI Trial

Cost-effectiveness Of Transcatheter Left Atrial Appendage Occlusion Compared With 5 Alternative Anticoagulation Strategies For Stroke Prevention In Atrial Fibrillation: A Markov...

Novel Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation

4q25 and Prediction of Atrial Fibrillation: How Can This Information Help the Clinician?

Will Transcatheter Left Atrial Appendage Closure Transform Management of Atrial Fibrillation?

Lone Surgical Treatment of Atrial Fibrillation: Meaningful Progress in the Past 15 Years?

Does Atrial Fibrillation Ablation Reduce Cardioembolic Stroke?

Case 4: The Patient with Atrial Fibrillation Presenting with an Acute Coronary Syndrome

Anticoagulation Choices for Atrial Fibrillation: Which Drug for Which Patient?

Strategies for the ACS Patient with Chronic Atrial Fibrillation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content